Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
AVTE Stock Forecast 2026-2027
$20.95
Current Price
$607.24M
Market Cap
Buy 0
Hold 4
Sell 0
Wall St Analyst Ratings
Distance to AVTE Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
AVTE Price Momentum
0.0%
1 Week Change
+24.2%
1 Month Change
+120.3%
1 Year Change
+35.8%
Year-to-Date Change
-25.2%
From 52W High of $28.00
+214.1%
From 52W Low of $6.67
📊 TOP ANALYST CALLS
Did AVTE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Aerovate is one of their latest high-conviction picks.
Latest AVTE Stock Price Targets & Analyst Predictions
AVTE has shown a year-to-date change of 35.8% and a 1-year change of 120.3%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for AVTE. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AVTE Analyst Ratings
0
Buy
4
Hold
0
Sell
AVTE Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $20.95
Latest AVTE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AVTE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 18, 2024 | Evercore ISI Group | Liisa Bayko | In-Line | Downgrade | $2.00 |
| Jun 18, 2024 | Guggenheim | Vamil Divan | Neutral | Downgrade | $N/A |
| Jun 18, 2024 | Wells Fargo | Tiago Fauth | Equal-Weight | Downgrade | $2.00 |
| Jun 18, 2024 | TD Cowen | Joseph Thome | Hold | Downgrade | $N/A |
| Jun 17, 2024 | Jefferies | Eun Yang | Hold | Downgrade | $2.00 |
| Jun 17, 2024 | BTIG | Julian Harrison | Neutral | Downgrade | $N/A |
| Jun 6, 2024 | Wedbush | Laura Chico | Outperform | Reiterates | $41.00 |
| May 22, 2024 | Wedbush | Laura Chico | Outperform | Reiterates | $41.00 |
| May 14, 2024 | Wedbush | Laura Chico | Outperform | Reiterates | $41.00 |
| Apr 1, 2024 | Wells Fargo | Tiago Fauth | Overweight | Maintains | $35.00 |
| Mar 25, 2024 | Jefferies | Eun Yang | Buy | Assumes | $65.00 |
| Mar 1, 2023 | Guggenheim | Vamil Divan | Buy | Initiates | $36.00 |
| Dec 6, 2022 | BTIG | Julian Harrison | Buy | Upgrade | $27.00 |
| Aug 16, 2022 | BTIG | Julian Harrison | Neutral | Downgrade | $N/A |
| Feb 11, 2022 | BTIG | Buy | Initiates | $N/A | |
| Jul 26, 2021 | Evercore ISI Group | Outperform | Initiates | $N/A | |
| Jul 26, 2021 | Cowen & Co. | Outperform | Initiates | $N/A | |
| Jul 26, 2021 | Wedbush | Outperform | Initiates | $N/A | |
| Jul 26, 2021 | Jefferies | Buy | Initiates | $N/A |
Jade Biosciences Inc. (AVTE) Competitors
The following stocks are similar to Aerovate based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Jade Biosciences Inc. (AVTE) Financial Data
Valuation Metrics
Market Cap
$607.24M
Enterprise Value
$573.90M
P/E Ratio
N/A
PEG Ratio
N/A
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
EPS Growth
N/A
Financial Health
Cash/Price Ratio
N/A
Current Ratio
20.9x
Debt/Equity
0.0x
ROE
-91.1%
ROA
-86.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Jade Biosciences Inc. (AVTE) Business Model
About Jade Biosciences Inc.
What They Do
Develops therapies for autoimmune diseases.
Business Model
Jade Biosciences Inc. operates as a clinical-stage biotechnology company, focusing on developing monoclonal antibodies for treating autoimmune diseases. The company generates potential revenue through the advancement of its drug candidates, particularly JADE101 for IgAN, as they progress through clinical trials and seek regulatory approvals.
Additional Information
Founded in 2024 and based in Waltham, Massachusetts, Jade Biosciences is leveraging licensed discovery-stage assets from Paragon Therapeutics to address significant unmet medical needs in the field of inflammation and immunology. The company is currently conducting Phase 1 studies for its lead candidate, with plans for Phase 2 trials, highlighting its commitment to innovation in healthcare.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
55
CEO
Mr. Tom Frohlich
Country
United States
IPO Year
2021
Website
jadebiosciences.comJade Biosciences Inc. (AVTE) Latest News & Analysis
Latest News
Quick Summary
Jade Biosciences, formed from the merger with Aerovate Therapeutics, will focus on autoimmune therapies. Lead candidate JADE-001 is set for clinical trials in late 2025, with data in early 2026. Trading begins April 29, 2025, under the ticker "JBIO."
Why It Matters
The merger creates a new player in the biotech sector focused on autoimmune therapies, potentially attracting investor interest as it progresses towards clinical trials and Nasdaq listing.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Aerovate Therapeutics, Inc. announced a 1-for-35 reverse stock split and that its stockholders approved the merger with Jade Biosciences, Inc.
Why It Matters
A reverse stock split can impact share liquidity and market perception, while the merger may alter the company's valuation and growth potential, influencing investor sentiment and future stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Aerovate Therapeutics plans to declare a cash dividend of $67.6 – 69.6 million for pre-Merger stockholders following its merger with Jade Biosciences.
Why It Matters
The anticipated cash dividend indicates financial stability and shareholder value enhancement for Aerovate, potentially attracting investors seeking returns amid merger activity.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Aerovate Therapeutics has declared a special cash dividend of $69.6 million, or approximately $2.40 per share, related to its merger with Jade Biosciences, effective as per the merger agreement.
Why It Matters
A special cash dividend of $2.40 per share signals financial strength and may attract investors, while the merger announcement suggests strategic growth potential for Aerovate Therapeutics.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Charles C. Foti, Jr. and Kahn Swick & Foti, LLC are investigating the merger between Aerovate Therapeutics (AVTE) and Jade Biosciences, focusing on shareholder equity in the deal.
Why It Matters
The investigation into Aerovate's merger may signal potential issues with the deal's fairness, affecting shareholder value and market confidence in the combined company.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Halper Sadeh LLC is investigating the fairness of Aerovate Therapeutics' merger with Jade Biosciences, as Aerovate shareholders will hold about 1.6% of the new entity post-merger.
Why It Matters
The investigation into Aerovate's merger raises concerns about shareholder value, potentially impacting stock performance and investor confidence in the deal's fairness.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About AVTE Stock
What is Jade Biosciences Inc.'s (AVTE) stock forecast for 2027?
Analyst forecasts for Jade Biosciences Inc. (AVTE) are not currently available. The stock is trading at $20.95.
Is AVTE stock a good investment in 2027?
According to current analyst ratings, AVTE has 0 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $20.95. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AVTE stock?
Price predictions from Wall Street analysts for AVTE are not currently available. The stock is trading at $20.95.
What is Jade Biosciences Inc.'s business model?
Jade Biosciences Inc. operates as a clinical-stage biotechnology company, focusing on developing monoclonal antibodies for treating autoimmune diseases. The company generates potential revenue through the advancement of its drug candidates, particularly JADE101 for IgAN, as they progress through clinical trials and seek regulatory approvals.
What is the highest forecasted price for AVTE Jade Biosciences Inc.?
Price targets from Wall Street analysts for AVTE are not currently available. The stock is trading at $20.95.
What is the lowest forecasted price for AVTE Jade Biosciences Inc.?
Price targets from Wall Street analysts for AVTE are not currently available. The stock is trading at $20.95.
What is the overall AVTE consensus from analysts for Jade Biosciences Inc.?
The overall analyst consensus for AVTE is neutral. Out of 8 Wall Street analysts, 0 rate it as Buy, 4 as Hold, and 0 as Sell.
How accurate are AVTE stock price projections?
Stock price projections, including those for Jade Biosciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 16, 2026 1:37 AM UTC